

Summit Therapeutics PLC

13:13 12 Jun 2019

Summit Therapeutics reduces first quarter losses

Summit Therapeutics PLC (LON:SUMM) has reported a reduced loss for its first quarter and increased its cash reserves.

For the three months ended 30 April 2019, the AIM-listed firm reported an operating loss of £4.8m, down from £6.6m a year ago.

Revenues, meanwhile, fell to £249,000 from £3.87m year-on-year, which the company said was related to its Sarepta licence and collaboration agreement following the group's decision to discontinue development of its ezutromid treatment in June 2018.

READ: Summit Therapeutics soars as it hails potential of very early stage antibiotic

Summit also ended the quarter with a cash balance of £28.3m compared to £26.9m a year ago, adding that it had enough funds to support its operating expenses and capital expenditure until the end of January 2020.

The group's chief executive, Glyn Edwards, said that the company was taking a leadership role in developing new classes of antibiotics which had the potential to combat the "rising threat" of antibiotic resistance.

"We believe these new class antibiotics have the potential to transform patient lives and that it is possible to show clear advantages over standard of care treatments and cost effectiveness during development. With this differentiated approach, we believe we will have the opportunity to be commercially successful", he added.

The firm is currently developing three flagship treatments; Ridinilazole, designed to treat *Clostridium difficile* which can cause diarrhoea, SMT-571 for Gonorrhoea and DDS-04 which is aiming to treat Enterobacteriaceae, a family of bacteria that includes salmonella.

In April, the company said the pre-clinical DDS-04 had successfully tackled Enterobacteriaceae in animals with urinary tract infections.

In early afternoon trading on Wednesday, Summit shares were steady at 23p.

Price: 22p

Market Cap: £35.31M

1 Year Share Price Graph



June 2018 December 2018 June 2019

Share Information

Code: SUMM

Listing: AIM

52 week High Low
204.00p 9.50p

Sector: Pharma & Biotech

Website: www.summitplc.com

Company Synopsis:

Summit Therapeutics is a leader in antibiotic innovation. Summit's new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. The company is currently developing new mechanism antibiotics for infections caused by C. difficile, N.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content

published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.